KI
RVNC

Kula Investments’s Revance Therapeutics, Inc. RVNC Stock Holding History

Kula Investments’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$1.02M Buy
31,545
+13,584
+76% +$423K 0.25% 121
2022
Q4 		$332K Buy
+17,961
New +$411K 0.1% 356

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Kula Investments's RVNC Position: Q1 2023 in Review

Kula Investments increased its Revance Therapeutics, Inc. (RVNC) stake by 76% in Q1 2023, buying an estimated $423K and bringing the position to 31,545 shares worth $1.02M. The position accounts for 0.25% of the portfolio, ranked #121.

Kula Investments first reported a position in RVNC in Q4 2022 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

  • Kula Investments held 31,545 shares of Revance Therapeutics, Inc. worth $1.02M as of Q1 2023.
  • Kula Investments bought 13,584 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $423K.
  • Revance Therapeutics, Inc. made up 0.25% of Kula Investments's portfolio in Q1 2023, its #121 holding.
  • Kula Investments first reported a position in Revance Therapeutics, Inc. in Q4 2022 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.